The SA articles gave a very carefully developed argument as to why a 50x valuation for a purchase could be feasible, and I haven't seen anyone destroy the basic assumption, which is that cpulse is great technology, with no immediate competition, in a large health need, and indeed one that saves money due to reduced hospitalisation.
Matthews response: it's just plain silly.
Ok, specifically what's wrong with the arguments put forward by SA? Try some constructive discussion instead of another trip round the "Rosa is to blame for everything" loop. What outcome are you expecting?
- Forums
- ASX - By Stock
- SHC
- More Changes at SSH
More Changes at SSH, page-14
-
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)